박무림 교수 연구실
article|
인용수 7
·2022
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
Seo‐Yeon Ahn, Sang Kyun Son, Gyu Hyung Lee, Inho Kim, June‐Won Cheong, Won Sik Lee, Byung Soo Kim, Deog‐Yeon Jo, Chul Won Jung, Chu Myoung Seong, Jae Hoon Lee, Young Jin Yuh, Min Kyoung Kim, Hun-Mo Ryoo, Moo‐Rim Park, Su-Hee Cho, Hoon‐Gu Kim, Dae Young Zang, Jinny Park, Hawk Kim, Se-Ryeon Lee, Sung‐Hyun Kim, Myung Hee Chang, Ho Sup Lee, Chul Won Choi, Jihyun Kwon, Sung-Nam Lim, Sukjoong Oh, Inkyung Joo, Dong‐Wook Kim
IF 2.8Blood Research
초록
This PMS study shows consistent results in terms of safety and efficacy compared with previous studies. Nilotinib was well tolerated and efficacious in adult Korean patients with Ph+ CML in routine clinical practice settings.
키워드
NilotinibMedicineAdverse effectInternal medicineObservational studyMyeloid leukemiaClinical trialTyrosine-kinase inhibitorPharmacovigilancePostmarketing surveillance